Cargando…

Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia

Chimeric antigen receptor T (CAR-T) cells targeting CD19 have achieved great clinical responses in patients with relapsed or refractory (R/R) acute B lymphoblastic leukemia. However, severe adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yinqiang, Zhou, Fen, Wu, Zhuolin, Li, Yingnan, Li, Chenggong, Du, Mengyi, Luo, Wenjing, Kou, Haiming, Lu, Cong, Mei, Heng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253384/ https://www.ncbi.nlm.nih.gov/pubmed/35799791 http://dx.doi.org/10.3389/fimmu.2022.914959

Ejemplares similares

Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis
por: Luo, Wenjing, et al.
Publicado: (2022)

Plasma proteomic and metabolomic signatures of B‐ALL patients during CAR‐T cell therapy
por: Wu, Jianghua, et al.
Publicado: (2023)

P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA
por: Luo, Wenjing, et al.
Publicado: (2023)

Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma
por: Du, Mengyi, et al.
Publicado: (2022)

IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy
por: Wang, Xindi, et al.
Publicado: (2023)

P1404: IL-10 PLUS THE EASIX SCORE PREDICT BLEEDING EVENTS AFTER ANTI-CD19 CAR T-CELL THERAPY
por: Wang, Xindi, et al.
Publicado: (2023)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023)

Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
por: Li, Chenggong, et al.
Publicado: (2023)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
por: Dufranc, Etienne, et al.
Publicado: (2020)

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy
por: Li, Chenggong, et al.
Publicado: (2020)

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma
por: Xu, Jiuhui, et al.
Publicado: (2023)

Role of IL6R Genetic Variants in Predicting Response to Tocilizumab in Patients with Rheumatoid Arthritis
por: Sainz, Luis, et al.
Publicado: (2022)

IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update
por: Oliveira, Mariana L., et al.
Publicado: (2019)

Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6
por: Li, Pan, et al.
Publicado: (2021)

Dual STAT-3 and IL-6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL-6/IL-6R/STAT-3 axis
por: Méndez-Clemente, Anibal, et al.
Publicado: (2022)

Clinical Value of IL6R Gene Variants as Predictive Biomarkers for Toxicity to Tocilizumab in Patients with Rheumatoid Arthritis
por: Sainz, Luis, et al.
Publicado: (2022)

Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia
por: Oliveira, Mariana L., et al.
Publicado: (2022)

Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T
por: Shiqi, Li, et al.
Publicado: (2023)

P356: PHASE 1/2 DOSE-ESCALATION STUDY OF ANTI-CD7 ALLOGENIC CAR-T CELL IN RELAPSED OR REFRACTORY(R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA(T-ALL/LBL)
por: Ghobadi, Armin, et al.
Publicado: (2023)

Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy
por: Stern, Lawrence A., et al.
Publicado: (2022)

Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph(+) B cell acute lymphoblastic leukemia
por: Han, Lu, et al.
Publicado: (2022)

Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: A systematic review and meta-analysis
por: Luo, Lili, et al.
Publicado: (2022)

Clinical development of IL13Rα2-targeting CAR T cells for the treatment of glioblastoma
por: Brown, Christine E, et al.
Publicado: (2015)

Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma
por: Silva, Ana, et al.
Publicado: (2021)

Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19
por: Parums, Dinah V.
Publicado: (2021)

Tocilizumab is recommended for the treatment of severe COVID-19
por: Zhou, Yonggang, et al.
Publicado: (2020)

CD19/BAFF-R dual targeted CAR T cells for treatment of mixed antigen-negative variants of acute lymphoblastic leukemia
por: Wang, Xiuli, et al.
Publicado: (2022)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
por: Mei, Heng, et al.
Publicado: (2021)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
por: Sun, Yao, et al.
Publicado: (2021)

P1413: DOES TOCILIZUMAB INCREASE THE RISK OF INFECTIONS IN PATIENTS UNDERGOING CAR-T THERAPY?
por: Greenhalgh, Sophie, et al.
Publicado: (2023)

A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy
por: Muhammad, Niaz, et al.
Publicado: (2022)

Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect in vivo
por: Silvestre, Renata Nacasaki, et al.
Publicado: (2023)

Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias
por: Shochat, Chen, et al.
Publicado: (2011)

Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias
por: Shochat, Chen, et al.
Publicado: (2011)

EUPATI Guidance for Patient Involvement in Medicines Research and Development (R&D); Guidance for Pharmaceutical Industry-Led Medicines R&D
por: Warner, Kay, et al.
Publicado: (2018)

MiR-21 and Tocilizumab interactions improve COVID-19 myocarditis outcomes
por: Hossein Heydari, Amir, et al.
Publicado: (2023)

Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations
por: Senkevitch, Emilee, et al.
Publicado: (2018)

Why tocilizumab could be an effective treatment for severe COVID-19?
por: Fu, Binqing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oqafgvi8a1r0d7ilhvijc5tqno